The Evolution of Antibody–Drug Conjugates in Breast Cancer

The Evolution of Antibody–Drug Conjugates in Breast Cancer

Wednesday, September 30, 2020 in Barcelona,
Live Meeting -- CCIB (Centre Convencions International Barcelona), 5:30 PM CET
MIRO: Room 117


17:30 Registration and Reception
18:00 Welcome and Program Overview
18:05 T-DM1: Setting the Stage for ADC Development in Breast Cancer
18:20 Next-Generation HER2-Directed ADCs in Development for HER2-Positive Breast Cancer
18:45 ADCs Beyond HER2-Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets
19:05 Final Thoughts and Audience Question and Answer Session


Program Chair
Michael Untch, MD, PhD

Director of the Clinic
Gynecology, Gyencologic Oncology and Obstetrics
Helios Hospital Berlin-Buch
Berlin, Germany

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate new and emerging antibody–drug conjugate therapies into breast cancer treatment.

Target Audience 
This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.

Learning Objectives 

  • Explain the medical rationale and key advances in next-generation antibody–drug conjugates in breast cancer treatment
  • Integrate available and emerging HER2-directed antibody–drug conjugates for treatment of patients with HER2-positive breast cancer
  • Assess clinical trial results for newer antibody–drug conjugates in various breast cancer subsets


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Education

Credit Designation

CCO designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.